drugset / Trial / NCT01261923

Pharmacokinetics of 9-cis-retinoic Acid (Alitretinoin, Toctino®) in Patients With Hepatic Disease

NCT01261923

Phase 1/2 Completed 16 enrolled University Hospital, Gentofte, Copenhagen
Non-randomizedParallel-groupOpen-label

Summary

This study aims to investigate whether liver patients may tolerate alitretinoin by comparing metabolism in 8 such patients with the metabolism in 8 healthy controls

Timeline

Start
2010-12
Primary completion
2011-08
Completion
2011-08

Drugs

EvaluationDrugModalityDoseRoute
Subject alitretinoin Other / unclassified 30 mg Oral

Indications